CSL Behring announced that the first patient has received U.S. FDA approved HEMGENIXfor hemophilia B in the United States. HEMGENIX is the first and only gene therapy for the treatment of adults with hemophilia B who currently use factor IX prophylaxis therapy, or have current or historical life-threatening bleeding, or have repeated, serious spontaneous bleeding episodes.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CSLLY: